givinostat
Commercial- Indications
- Duchenne muscular dystrophy
Company intelligence / Profile preview
ITF Therapeutics
Concord, Massachusetts, United Statesitftherapeutics.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
ITF Therapeutics launched in January 2024 as the U.S. rare disease affiliate of Italfarmaco. Its lead product, DUVYZAT™ (givinostat), a histone deacetylase inhibitor for Duchenne muscular dystrophy in patients aged six and older regardless of genetic mutation, received FDA approval on March 21, 2024 and is now commercially available in the U.S.[2][5] The company has rapidly built out its team and infrastructure to support commercialization and patient access.
- Therapeutic areas
- Rare Diseases
- Modalities
- Small molecules (notably, histone deacetylase inhibitors)[5]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaborates closely with patient advocacy groups in rare diseases; no major pharma partnerships disclosed beyond relationship with parent Italfarmaco[1][6].
Beyond the preview
Go deeper on ITF Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITF Therapeutics.